Form 4: Theravance Biopharma Exec's Future Share Withholding

A Theravance Biopharma executive reported a future disposition of shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Rhonda Farnum, SVP, Communications & Medical Affairs at Theravance Biopharma US, LLC, reported a disposition of 9,096 ordinary shares of Theravance Biopharma, Inc.
• The transaction is scheduled for August 20, 2025, and is for shares withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• The shares were valued at $13.39 per share for the purpose of the withholding.
• Following this transaction, Ms. Farnum will beneficially own 317,822 ordinary shares directly.
• This was a transaction with the issuer and did not involve an open market sale.

Sentiment

Score: 5

Explanation: The transaction is a routine administrative event related to executive compensation and tax obligations, neither significantly positive nor negative for the company's operational or financial outlook.

Positives

• The transaction indicates the vesting of previously granted restricted stock units, which represents earned compensation for the executive.

Negatives

• The disposition of shares, even for tax purposes, reduces the executive's direct ownership in the company.

Future Outlook

The filing does not provide any forward-looking statements or guidance beyond the scheduled transaction date.

Industry Context

This routine insider transaction, specifically a tax withholding related to equity compensation, is a common occurrence across all industries, particularly in biotechnology where executive compensation often includes significant equity components. It does not reflect on broader industry trends or competitive positioning.

Related Party Transactions

• The transaction involved the withholding of shares by the issuer (Theravance Biopharma, Inc.) from an executive (Rhonda Farnum) to satisfy tax obligations, which is considered a related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-open market transaction for tax purposes, not indicative of a change in company fundamentals or executive sentiment.
• Employees: No direct impact beyond the executive involved.

Key Dates

Keywords

Theravance Biopharma, TBPH, Form 4, Insider Transaction, Share Withholding, Restricted Stock Units, Executive Compensation, Rhonda Farnum